These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9682385)

  • 1. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.
    Coulter A; Wong TY; Drane D; Bates J; Macfarlan R; Cox J
    Vaccine; 1998 Jul; 16(11-12):1243-53. PubMed ID: 9682385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use.
    Deliyannis G; Jackson DC; Dyer W; Bates J; Coulter A; Harling-McNabb L; Brown LE
    Vaccine; 1998 Dec; 16(20):2058-68. PubMed ID: 9796065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of priming on subsequent response to inactivated influenza vaccine.
    Potter CW; Jennings R
    Vaccine; 2003 Feb; 21(9-10):940-5. PubMed ID: 12547606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines.
    Rimmelzwaan GF; Nieuwkoop N; Brandenburg A; Sutter G; Beyer WE; Maher D; Bates J; Osterhaus AD
    Vaccine; 2000 Dec; 19(9-10):1180-7. PubMed ID: 11137255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ISCOMs/MPLA-Adjuvanted SDAD Protein Nanoparticles Induce Improved Mucosal Immune Responses and Cross-Protection in Mice.
    Zhu W; Park J; Pho T; Wei L; Dong C; Kim J; Ma Y; Champion JA; Wang BZ
    Small; 2023 Aug; 19(34):e2301801. PubMed ID: 37162451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
    Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and potential application of ISCOMs in veterinary medicine.
    Morein B; Hu KF; Abusugra I
    Adv Drug Deliv Rev; 2004 Jun; 56(10):1367-82. PubMed ID: 15191787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix.
    Fossum C; Bergström M; Lövgren K; Watson DL; Morein B
    Cell Immunol; 1990 Sep; 129(2):414-25. PubMed ID: 2383899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.
    Ben Ahmeida ET; Gregoriadis G; Potter CW; Jennings R
    Vaccine; 1993 Oct; 11(13):1302-9. PubMed ID: 8296483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant.
    Bengtsson KL; Sjölander A
    Vaccine; 1996 Jun; 14(8):753-60. PubMed ID: 8817821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes.
    Sambhara S; Woods S; Arpino R; Kurichh A; Tamane A; Underdown B; Klein M; Lövgren Bengtsson K; Morein B; Burt D
    J Infect Dis; 1998 May; 177(5):1266-74. PubMed ID: 9593011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins.
    Sjölander A; Lövgren Bengtsson K; Johansson M; Morein B
    Scand J Immunol; 1996 Feb; 43(2):164-72. PubMed ID: 8633196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
    Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
    Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice.
    Zhang J; Miao J; Han X; Lu Y; Deng B; Lv F; Zhao Y; Ding C; Hou J
    BMC Vet Res; 2018 Dec; 14(1):415. PubMed ID: 30577861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens.
    Mowat AM; Maloy KJ; Donachie AM
    Immunology; 1993 Dec; 80(4):527-34. PubMed ID: 7508416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis.
    da Fonseca DP; Frerichs J; Singh M; Snippe H; Verheul AF
    Vaccine; 2000 Aug; 19(1):122-31. PubMed ID: 10924794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.
    Ghazi HO; Erturk M; Stannard LM; Faulkner M; Potter CW; Jennings R
    Arch Virol; 1995; 140(6):1015-31. PubMed ID: 7611875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).
    Ennis FA; Cruz J; Jameson J; Klein M; Burt D; Thipphawong J
    Virology; 1999 Jul; 259(2):256-61. PubMed ID: 10388649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
    J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.